AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Enhertu, an ADC that targets human epidermal ... which uses a dual cleavage mechanism (extracellular cleavage in the tumor microenvironment and intracellular cleavage in lysosomes) to enable ...

Given its novel mechanism of action and proven efficacy ... Tukysa improving survival for HER2+ brain metastases, plus Enhertu and other antibody-drug conjugates, and new targeted therapies ...

Studies have suggested that HER2 alterations may also serve as a resistance mechanism in up to 10% of ... Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), which is ...

When they bind to each other, the immune system fails to recognize the cancer cell and switches off its defense mechanism marking the cancer cell ... drugs” like fam-trastuzumab deruxtecan (Enhertu) ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Authlete, a leading implementer of OAuth 2.0 and OpenID Connect (OIDC), announced today the launch of Authlete 3.0, offering support for OpenID for Verifiable Credential Issuance (OID4VCI). This new ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU® (fam-trastuzumab ...